Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

How Much Lost Ground Can the S&P 500 Bulls Recover?

Stocks couldn’t build on Wednesday’s gains, and the bulls had to face selling pressure during yesterday’s regular session. While they’ve dealt with a good part of the intraday downswing, they couldn&CloseCurlyQuot...

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...

The S&P 500 Bull Keeps Climbing the Wall of Worry

How close to its end is this S&P 500 consolidation are we – will the rebound meet its spark? Yesterday's session carries signs of the upcoming move, which I think will be higher. As said yesterday – in the battle of narratives, the corona second wave fears still play second fi...